In this study, we proposed that YHB may serve as a potential therapeutic agent by inhibiting the proliferation and migration of VSMCs induced by PDGF-BB, thus preventing arteriosclerosis and restenosis due to the following: (i) YHB inhibits the proliferation of VSMCs by downregulating cell cycle regulatory proteins; (ii) YHB regulates the proliferation and migration of VSMCs via targeted signals such as mTOR, p38, and FAK; (iii) YHB inhibits the expression of cell cycle regulatory proteins through the regulation of FOXO3a. Here, RCC1 is linked to arteriosclerosis disorder.